189 related articles for article (PubMed ID: 18609705)
1. Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein.
Sieben M; Herzer K; Zeidler M; Heinrichs V; Leuchs B; Schuler M; Cornelis JJ; Galle PR; Rommelaere J; Moehler M
World J Gastroenterol; 2008 Jun; 14(24):3819-28. PubMed ID: 18609705
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells.
Herzer K; Weyer S; Krammer PH; Galle PR; Hofmann TG
Cancer Res; 2005 Dec; 65(23):10830-7. PubMed ID: 16322229
[TBL] [Abstract][Full Text] [Related]
3. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53.
Herzer K; Hofmann TG; Teufel A; Schimanski CC; Moehler M; Kanzler S; Schulze-Bergkamen H; Galle PR
Cancer Res; 2009 Feb; 69(3):855-62. PubMed ID: 19141642
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide and promyelocytic leukemia protein-adenovirus synergistically inhibit in vitro and in vivo growth of a hepatoma cell line.
Cui L; Zhang S; Zhang W; Hu Z; Cao Z; Li T
Oncol Res; 2010; 18(7):305-14. PubMed ID: 20377131
[TBL] [Abstract][Full Text] [Related]
5. Promyelocytic leukaemia protein links DNA damage response and repair to hepatitis B virus-related hepatocarcinogenesis.
Chung YL; Wu ML
J Pathol; 2013 Aug; 230(4):377-87. PubMed ID: 23620081
[TBL] [Abstract][Full Text] [Related]
6. Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.
Zhang X; Yang XR; Sun C; Hu B; Sun YF; Huang XW; Wang Z; He YF; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J
Cancer Lett; 2015 Sep; 366(1):112-22. PubMed ID: 26118777
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C-associated liver carcinogenesis: role of PML nuclear bodies.
Herzer K; Gerken G; Hofmann TG
World J Gastroenterol; 2014 Sep; 20(35):12367-71. PubMed ID: 25253937
[TBL] [Abstract][Full Text] [Related]
8. Concordant expression of proto-oncogene promyelocytic leukemia and major histocompatibility antigen HLA class I in human hepatocellular carcinoma.
Xia M; Zhang JQ; Shen YQ; Xu LH; Chen AQ; Miao FQ; Xie W
Tissue Antigens; 2007 Oct; 70(4):272-82. PubMed ID: 17767548
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitor, methyl 2,5-dihydromethylcinnimate, induces PML nuclear body formation and apoptosis in tumor cells.
Komura N; Asakawa M; Umezawa K; Segawa K
Exp Cell Res; 2007 Aug; 313(13):2753-65. PubMed ID: 17585903
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma and chemotherapy: the role of p53.
Brito AF; Abrantes AM; Pinto-Costa C; Gomes AR; Mamede AC; Casalta-Lopes J; Gonçalves AC; Sarmento-Ribeiro AB; Tralhão JG; Botelho MF
Chemotherapy; 2012; 58(5):381-6. PubMed ID: 23257706
[TBL] [Abstract][Full Text] [Related]
11. Knocking down PML impairs p53 signaling transduction pathway and suppresses irradiation induced apoptosis in breast carcinoma cell MCF-7.
Bao-Lei T; Zhu-Zhong M; Yi S; Jun-Jie Q; Yan D; Hua L; Bin L; Guo-Wei Z; Zhi-Xian S
J Cell Biochem; 2006 Feb; 97(3):561-71. PubMed ID: 16215989
[TBL] [Abstract][Full Text] [Related]
12. AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.
Li Q; He Y; Wei L; Wu X; Wu D; Lin S; Wang Z; Ye Z; Lin SC
Oncogene; 2011 Mar; 30(10):1194-204. PubMed ID: 21057547
[TBL] [Abstract][Full Text] [Related]
13. A novel interaction of nucleophosmin with BCL2-associated X protein regulating death evasion and drug sensitivity in human hepatoma cells.
Lo SJ; Fan LC; Tsai YF; Lin KY; Huang HL; Wang TH; Liu H; Chen TC; Huang SF; Chang CJ; Lin YJ; Yung BY; Hsieh SY
Hepatology; 2013 May; 57(5):1893-905. PubMed ID: 23258611
[TBL] [Abstract][Full Text] [Related]
14. Andrographolide enhances 5-fluorouracil-induced apoptosis via caspase-8-dependent mitochondrial pathway involving p53 participation in hepatocellular carcinoma (SMMC-7721) cells.
Yang L; Wu D; Luo K; Wu S; Wu P
Cancer Lett; 2009 Apr; 276(2):180-8. PubMed ID: 19097688
[TBL] [Abstract][Full Text] [Related]
15. Promyelocytic leukemia protein-induced growth suppression and cell death in liver cancer cells.
Son SH; Yu E; Choi EK; Lee H; Choi J
Cancer Gene Ther; 2005 Jan; 12(1):1-11. PubMed ID: 15529177
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling.
Hubackova S; Novakova Z; Krejcikova K; Kosar M; Dobrovolna J; Duskova P; Hanzlikova H; Vancurova M; Barath P; Bartek J; Hodny Z
Cell Cycle; 2010 Aug; 9(15):3085-99. PubMed ID: 20699642
[TBL] [Abstract][Full Text] [Related]
17. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
18. Dissection of cell context-dependent interactions between HBx and p53 family members in regulation of apoptosis: a role for HBV-induced HCC.
Knoll S; Fürst K; Thomas S; Villanueva Baselga S; Stoll A; Schaefer S; Pützer BM
Cell Cycle; 2011 Oct; 10(20):3554-65. PubMed ID: 22030623
[TBL] [Abstract][Full Text] [Related]
19. PML suppresses IL-6-induced STAT3 activation by interfering with STAT3 and HDAC3 interaction.
Kato M; Muromoto R; Togi S; Iwakami M; Kitai Y; Kon S; Oritani K; Matsuda T
Biochem Biophys Res Commun; 2015 May; 461(2):366-71. PubMed ID: 25892518
[TBL] [Abstract][Full Text] [Related]
20. Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation.
Yang S; Jeong JH; Brown AL; Lee CH; Pandolfi PP; Chung JH; Kim MK
J Biol Chem; 2006 Sep; 281(36):26645-54. PubMed ID: 16835227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
